Impact of patient characteristics on the risk of influenza/ILI-related complications.

Authors:
Irwin DE; Weatherby LB; Huang WY; Rosenberg DM; Cook SF and 1 more

Journal:
BMC Health Serv Res

Publication Year: 2001

DOI:
10.1186/1472-6963-1-8

PMCID:
PMC57009

PMID:
11580874

View on PubMed View on PMC View Publisher
Journal Information

Full Title: BMC Health Serv Res

Abbreviation: BMC Health Serv Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Health Services Research

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Acceptance of assisted partner notification among HIV-positive adults with severe mental illness at…
Nante RW; Muyinda H; Kiweewa JM and 6 more (2024) - Transparency Score: 3/6
Access to automated comparative feedback reports in primary care - a study of intensity of use and …
Anell A; Arvidsson E; Dackehag M and 2 more (2024) - Transparency Score: 3/6
Access to quality care after injury in Northern Malawi: results of a household survey.
Whitaker J; Amoah AS; Dube A and 3 more (2024) - Transparency Score: 3/6
A closer look at the international health regulations capacities in Lebanon: a mixed method study.
Hassan M; Jamal D; El-Jardali F. (2024) - Transparency Score: 3/6
A collaboratively produced model of service design for children and young people with common mental…
Pryjmachuk S; Kirk S; Fraser C and 10 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests SC, W-YH, and DR were employees of Glaxo Wellcome (now GlaxoSmithKline), the manufacturer of zanamivir, at the time this study was carried out. DI, AMW, and LW were employees of lngenix Pharmaceutical Services, which received a research contract to perform this study from Glaxo Wellcome."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025